Kewaunee Scientific (US:KEQU)2025-12-12 14:41Sales Performance - Sales for the quarter were $70,096,000, an increase of 46.8% from $47,764,000 in the comparable period of the prior year[94] - Domestic sales for the quarter were $55,224,000, up 51.7% compared to $36,409,000 in the prior year[94] - International sales for the quarter were $14,872,000, up 31.0% from $11,355,000 in the comparable period of the prior year[94] Financial Metrics - Gross profit margin for the three months ended October 31, 2025 was 28.1%, down from 29.2% in the comparable quarter of the prior year[97] - Operating expenses for the three months ended October 31, 2025 were $15,613,000, or 22.3% of sales, compared to $9,518,000, or 19.9% of sales in the prior year[98] - Net earnings for the three months ended October 31, 2025 was $2,445,000, or $0.82 per diluted share, compared to $3,008,000, or $1.01 per diluted share in the prior year[103] - The effective income tax rate for the three months ended October 31, 2025 was 26.5%, compared to 23.3% for the same period in the prior year[100] Order Backlog and Working Capital - The Company's order backlog was $192.9 million at October 31, 2025, compared to $184.4 million at October 31, 2024[96] - The Company had working capital of $67,830,000 at October 31, 2025, compared to $64,651,000 at April 30, 2025[105] Growth Strategy - The Company remains focused on growth, both organically and inorganically, and is committed to making strategic investments to support this growth[109]